Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Thomas Wehrman"'
Autor:
Iain B. McInnes, Nicole L. Byers, Richard E. Higgs, Jonathan Lee, William L. Macias, Songqing Na, Robert A. Ortmann, Guilherme Rocha, Terence P. Rooney, Thomas Wehrman, Xin Zhang, Steven H. Zuckerman, Peter C. Taylor
Publikováno v:
Arthritis Research & Therapy, Vol 21, Iss 1, Pp 1-10 (2019)
Abstract Background The in vitro pharmacology of baricitinib, upadacitinib, and tofacitinib was evaluated to understand differences among these JAK inhibitors (JAKis) at the cellular level. Methods Peripheral blood mononuclear cells from healthy dono
Externí odkaz:
https://doaj.org/article/9199674c675b4aa38a99899ed7156b79
Autor:
Richard E. Higgs, Guilherme Rocha, Terence Rooney, Z. Xin, D. Dairaghi, Peter C. Taylor, J. Ross Terres, Iain B. McInnes, Thomas Wehrman, E. Wang
Publikováno v:
Annals of the Rheumatic Diseases. 79:1-2
Background:everal JAKi are now used for the treatment of RA; approved doses include baricitinib (bari) 2- and/or 4-mg QD, tofacitinib (tofa) 5-mg BID, upadacitinib (upa) 15-mg QD. The JAK selectivity these agents is proposed to vary across the class.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e5abd57a1acc5c9a333478f03584d84c
https://doi.org/10.1136/annrheumdis-2020-eular.755
https://doi.org/10.1136/annrheumdis-2020-eular.755
Autor:
S Na, Terence Rooney, William L. Macias, Peter C. Taylor, Thomas Wehrman, R Ortmann, Xin Zhang, Jonathan A. Lee, Iain B. McInnes, Steven H. Zuckerman, Richard E. Higgs, Guilherme Rocha, Nicole L. Byers
Publikováno v:
Arthritis Research & Therapy
Arthritis Research & Therapy, Vol 21, Iss 1, Pp 1-10 (2019)
Arthritis Research & Therapy, Vol 21, Iss 1, Pp 1-10 (2019)
Background The in vitro pharmacology of baricitinib, upadacitinib, and tofacitinib was evaluated to understand differences among these JAK inhibitors (JAKis) at the cellular level. Methods Peripheral blood mononuclear cells from healthy donors were i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::237c9f93dc57c1a2560a726fcd0871d4
https://pubmed.ncbi.nlm.nih.gov/31375130
https://pubmed.ncbi.nlm.nih.gov/31375130
Autor:
William L. Macias, Guilherme Rocha, Thomas Wehrman, Richard E. Higgs, Clementine Perrier, Peter C. Taylor, R Ortmann, Iain B. McInnes, Xiang Zhang, Jonathan A. Lee, Steven H. Zuckerman, S Na
Publikováno v:
Poster presentations.
Introduction Baricitinib (BARI), an oral selective Janus kinase (JAK) 1/2 inhibitor, approved in the EU for moderate to severe active RA. Objectives To compare in vitro cellular pharmacology of BARI to upadacitinib (ABT), filgotinib (FILGO), and tofa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0c0794b6ab68d4517f9c0b4408100b7b
https://doi.org/10.1136/annrheumdis-2018-ewrr2018.78
https://doi.org/10.1136/annrheumdis-2018-ewrr2018.78
Autor:
Iain McInnes, Richard Higgs, Guilherme Rocha, Xin Zhang, Jonathan Lee, Thomas Wehrman, William Macias, Steven Zuckerman, Peter Taylor, Maurizio Gentile
Publikováno v:
Novel technologies.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::87887fb465c991ee8e6195aba7b51c92
https://doi.org/10.1136/annrheumdis-2016-211053.2
https://doi.org/10.1136/annrheumdis-2016-211053.2
Autor:
William L. Macias, Guilherme Rocha, Iain B. McInnes, Peter C. Taylor, Richard E. Higgs, Thomas Wehrman, Steven H. Zuckerman, Jonathan A. Lee, Xin Zhang, Maurizio Gentile
Publikováno v:
Annals of the Rheumatic Diseases. 75:251.1-251
Background Baricitinib (bari) and tofacitinib (tofa) are selective JANUS kinase inhibitors (JAKi). In biochemical assays, bari exhibits greatest potency against JAK1 and JAK2, whereas that for tofa is against JAK1 and JAK3. Objectives To determine wh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4bc2f68e879b73e87f4fd206dd6ae6cc
https://doi.org/10.1136/annrheumdis-2016-eular.1512
https://doi.org/10.1136/annrheumdis-2016-eular.1512